Full text

Turn on search term navigation

© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.

Abstract

Simple Summary

Positron emission tomography (PET), typically combined with computed tomography (CT), has become a critical advanced imaging technique in oncology. With PET-CT, a radioactive molecule (radiotracer) is injected in the bloodstream and localizes to sites of tumor because of specific cellular features of the tumor that accumulate the targeting radiotracer. The CT scan, performed at the same time, provides information to facilitate assessment of the amount of radioactivity from deep or dense structures, and to provide detailed anatomic information. PET-CT has a variety of applications in oncology, including staging, therapeutic response assessment, restaging, and surveillance. This series of six review articles provides an overview of the value, applications, and imaging and interpretive strategies of PET-CT in the more common adult malignancies. The second article in this series addresses the use of PET-CT in breast cancer and other primary thoracic malignancies.

Abstract

Positron emission tomography combined with x-ray computed tomography (PET-CT) is an advanced imaging modality with oncologic applications that include staging, therapy assessment, restaging, and surveillance. This six-part series of review articles provides practical information to providers and imaging professionals regarding the best use of PET-CT for the more common adult malignancies. The second article of this series addresses primary thoracic malignancy and breast cancer. For primary thoracic malignancy, the focus will be on lung cancer, malignant pleural mesothelioma, thymoma, and thymic carcinoma, with an emphasis on the use of FDG PET-CT. For breast cancer, the various histologic subtypes will be addressed, and will include 18F fluorodeoxyglucose (FDG), recently Food and Drug Administration (FDA)-approved 18F-fluoroestradiol (FES), and 18F sodium fluoride (NaF). The pitfalls and nuances of PET-CT in breast and primary thoracic malignancies and the imaging features that distinguish between subcategories of these tumors are addressed. This review will serve as a resource for the appropriate roles and limitations of PET-CT in the clinical management of patients with breast and primary thoracic malignancies for healthcare professionals caring for adult patients with these cancers. It also serves as a practical guide for imaging providers, including radiologists, nuclear medicine physicians, and their trainees.

Details

Title
PET-CT in Clinical Adult Oncology: II. Primary Thoracic and Breast Malignancies
Author
Covington, Matthew F 1   VIAFID ORCID Logo  ; Koppula, Bhasker R 1 ; Fine, Gabriel C 1 ; Ahmed Ebada Salem 2 ; Wiggins, Richard H 1 ; Hoffman, John M 1 ; Morton, Kathryn A 3   VIAFID ORCID Logo 

 Department of Radiology and Imaging Sciences, University of Utah, Salt Lake City, UT 84132, USA; [email protected] (M.F.C.); [email protected] (B.R.K.); [email protected] (G.C.F.); [email protected] (A.E.S.); [email protected] (R.H.W.); [email protected] (J.M.H.) 
 Department of Radiology and Imaging Sciences, University of Utah, Salt Lake City, UT 84132, USA; [email protected] (M.F.C.); [email protected] (B.R.K.); [email protected] (G.C.F.); [email protected] (A.E.S.); [email protected] (R.H.W.); [email protected] (J.M.H.); Department of Radiodiagnosis and Intervention, Faculty of Medicine, Alexandria University, Alexandria 21526, Egypt 
 Department of Radiology and Imaging Sciences, University of Utah, Salt Lake City, UT 84132, USA; [email protected] (M.F.C.); [email protected] (B.R.K.); [email protected] (G.C.F.); [email protected] (A.E.S.); [email protected] (R.H.W.); [email protected] (J.M.H.); Intermountain Healthcare Hospitals, Summit Physician Specialists, Murray, UT 84123, USA 
First page
2689
Publication year
2022
Publication date
2022
Publisher
MDPI AG
e-ISSN
20726694
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2674321242
Copyright
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.